Anterior segment complications after dexamethasone implantations:real world data

被引:2
作者
Ayaz, Yusuf [1 ]
Pota, Cisil Erkan [2 ]
Basol, Ibrahim [1 ]
Dogan, Mehmet Erkan [1 ]
Sen, Elif Betul Turkoglu [1 ]
Unal, Mustafa [1 ]
机构
[1] Akdeniz Univ, Med Fac, Dept Ophthalmol, Antalya, Turkiye
[2] Antalya Manavgat State Hosp, Dept Ophthalmol, Antalya, Turkiye
关键词
Cataract; Diabetes; Glaucoma; Intravitreal dexamethasone; Ozurdex; Retinal vein occlusion; RETINAL-VEIN-OCCLUSION; MACULAR EDEMA SECONDARY; INTRAVITREAL DEXAMETHASONE; 0.7; MG; IMPLANT; SAFETY; EFFICACY; OZURDEX; TRIAL; MULTICENTER;
D O I
10.1007/s10792-023-02838-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PurposeWe aim to contribute to the literature in terms of treatment safety with our real world data by examining the anterior segment complications and follow-up results of patients who underwent dexamethasone implants in our clinic.MethodsThe records of patients treated with at least one intravitreal dexamethasone implant for various retinal diseases: diabetic macular edema (265 eyes), central retinal vein occlusion (45 eyes), retinal vein branch occlusion (91 eyes), postoperative cystoid macular edema (18 eyes), non-infectious uveitis (37 eyes) and other (14 eyes) between July 2013 and April 2020 were reviewed.ResultsAfter 925 injections were applied to 470 eyes of a total of 383 patients, the eyes were controlled during a mean follow-up of 24 months. No complications were detected in 328 eyes. Intraocular pressure (IOP) above 25 mmHg was detected in 97 eyes (20.6%) that had no previous history of ocular hypertension. Of these 97 eyes, 71 (73.1%) eyes with increased IOP were treated with topical monotherapy, 26 (26.8%) eyes were treated with topical combined therapy and 1 (1.03%) patient had glaucoma surgery. Cataracts requiring surgical intervention developed in 55 (%21.73) of 253 phakic eyes. Three patients have anterior chamber dislocation of dexamethasone, 1 patient was hospitalized with sterile endophthalmitis on the 7th day after the injection, and pars plana vitrectomy was performed.ConclusionThis study is the first long-term follow-up study in our country evaluating the safety of dexamethasone implant injections in various retinal diseases and presenting the first real world data. Cataract progression and increased IOP were found to be the most common side effects. We observed that the patient's diagnosis did not cause a statistically significant change in the observation of side effects. As a result of our findings, close follow-up of IOP after the injection of dexamethasone implants would be appropriate.
引用
收藏
页码:4279 / 4287
页数:9
相关论文
共 27 条
  • [11] Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema
    Klamann, Andre
    Boettcher, Katharina
    Ackermann, Philipp
    Geerling, Gerd
    Schargus, Marc
    Guthoff, Rainer
    [J]. OPHTHALMOLOGICA, 2016, 236 (04) : 181 - 185
  • [12] Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children
    Lei, Shaobo
    Lam, Wai-Ching
    [J]. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2015, 50 (03): : 236 - 241
  • [13] Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study
    Li, Xiaoxin
    Wang, Ningli
    Liang, Xiaoling
    Xu, Gezhi
    Li, Xiao-Yan
    Jiao, Jenny
    Lou, Jean
    Hashad, Yehia
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 256 (01) : 59 - 69
  • [14] SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension
    Malcles, Ariane
    Dot, Corinne
    Voirin, Nicolas
    Vie, Anne-Laure
    Agard, Emilie
    Bellocq, David
    Denis, Philippe
    Kodjikian, Laurent
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (07): : 1352 - 1359
  • [15] Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion
    Mayer, W. J.
    Wolf, A.
    Kernt, M.
    Kook, D.
    Kampik, A.
    Ulbig, M.
    Haritoglou, C.
    [J]. EYE, 2013, 27 (07) : 816 - 822
  • [16] Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience
    Mello Filho, Paulo
    Andrade, Gabriel
    Maia, Andre
    Maia, Mauricio
    Biccas Neto, Laurentino
    Muralha Neto, Acacio
    Brasil, Oswaldo Moura
    Minelli, Eduardo
    Dalloul, Claudio
    Iglicki, Matias
    [J]. OPHTHALMOLOGICA, 2019, 241 (01) : 9 - 16
  • [17] Cystoid Macular Edema after Complicated Cataract Surgery Resolved by an Intravitreal Dexamethasone 0.7-mg Implant
    Meyer, Linda M.
    Schoenfeld, Carl-Ludwig
    [J]. CASE REPORTS IN OPHTHALMOLOGY, 2011, 2 (03): : 319 - 322
  • [18] Secondary Glaucoma After Intravitreal Dexamethasone 0.7 mg Implant in Patients with Retinal Vein Occlusion: A One-Year Follow-Up
    Meyer, Linda M.
    Schoenfeld, Carl-Ludwig
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (06) : 560 - 565
  • [19] Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: Quantifying efficacy and safety
    Mishra S.K.
    Gupta A.
    Patyal S.
    Kumar S.
    Raji K.
    Singh A.
    Sharma V.
    [J]. International Journal of Retina and Vitreous, 4 (1)
  • [20] Dexamethasone implant (0.7 mg) in Indian patients with macular edema: Real-life scenario
    Nagpal, Manish
    Mehrotra, Navneet
    Juneja, Rakesh
    Jain, Hardik
    [J]. TAIWAN JOURNAL OF OPHTHALMOLOGY, 2018, 8 (03) : 141 - 148